Sign in
AMGN-AMGEN INC

Amgen Reports Strong Q4 2024 Earnings Despite Stock Decline from Clinical Trial Setback, Maintaining Positive Outlook for 2025

Monday

17 February, 2025

Amgen's Q4 2024 results reveal a remarkable revenue surge to $9.1 billion, driven by strategic acquisitions and a solid earnings performance. With a promising outlook for 2025 despite recent challenges, can Amgen continue to navigate the complexities of the pharmaceutical landscape?

article image for AMGN

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
55
Key Takeaways
  • Amgen reported impressive Q4 2024 revenues of $9.1 billion, marking a significant year-over-year increase.
  • The company's adjusted EPS of $5.31 demonstrates successful strategic initiatives and acquisitions, particularly the Horizon Therapeutics deal.
  • Despite FDA issues with AMG 513, Amgen's long-term revenue projections for 2025 remain optimistic, driven by key products.
  • The substantial dividend increase over the past decade underscores Amgen's dedication to returning value to shareholders.
  • Investment risks include recent challenges with drug approvals and reliance on a limited number of key products.
More on AMGEN INC
Read more insights on AMGEN INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.